{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:15:35Z","timestamp":1787501735833,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01968-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:04:22Z","timestamp":1764137062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The impact of sertraline treatment on obesity, inflammation, blood pressure, and lipid profiles: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Yonggui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periyannan","family":"Velu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousalya","family":"Prabahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Safargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Temuqile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1968_CR1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2017.05.003","volume":"219","author":"C Woody","year":"2017","unstructured":"Woody C, et al. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. J Affect Disord. 2017;219:86\u201392.","journal-title":"J Affect Disord"},{"key":"1968_CR2","unstructured":"Results GBD. 2025."},{"issue":"1","key":"1968_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/biologics5010007","volume":"5","author":"Y Matsuzaka","year":"2025","unstructured":"Matsuzaka Y, Yashiro R. Molecular regulation and therapeutic applications of brain-derived neurotrophic factor\u2013tropomyosin-related kinase B signaling in major depressive disorder though its interaction with vascular endothelial growth factor and N-methyl-D-aspartic acid receptors: a narrative review. Biologics. 2025;5(1):7.","journal-title":"Biologics"},{"key":"1968_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107322","author":"Y Yin","year":"2024","unstructured":"Yin Y, et al. Inflamed depression: a review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression. Pharmacol Res. 2024;207:107322. https:\/\/doi.org\/10.1016\/j.phrs.2024.107322","journal-title":"Pharmacol Res"},{"issue":"9","key":"1968_CR5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12091994","volume":"12","author":"A Alberti","year":"2024","unstructured":"Alberti A, et al. Factors associated with the development of depression and the influence of obesity on depressive disorders: a narrative review. Biomedicines. 2024;12(9):1994.","journal-title":"Biomedicines"},{"key":"1968_CR6","doi-asserted-by":"crossref","unstructured":"Chen I-C et al. Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 diabetes: A TriNetX-Based cohort study. Diabetes Res Clin Pract, 2025;223:112167.","DOI":"10.1016\/j.diabres.2025.112167"},{"key":"1968_CR7","doi-asserted-by":"crossref","first-page":"1328048","DOI":"10.3389\/fpsyt.2024.1328048","volume":"15","author":"L Xu","year":"2024","unstructured":"Xu L, et al. Depression and coronary heart disease: mechanisms, interventions, and treatments. Front Psychiatry. 2024;15:1328048.","journal-title":"Front Psychiatry"},{"key":"1968_CR8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","volume":"246","author":"JC Felger","year":"2013","unstructured":"Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199\u2013229.","journal-title":"Neuroscience"},{"issue":"8","key":"1968_CR9","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1074\/jbc.M112.408641","volume":"288","author":"R Isaac","year":"2013","unstructured":"Isaac R, et al. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic \u03b2 cells. J Biol Chem. 2013;288(8):5682\u201393.","journal-title":"J Biol Chem"},{"issue":"2","key":"1968_CR10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4306\/pi.2013.10.2.148","volume":"10","author":"M Beyazy\u00fcz","year":"2013","unstructured":"Beyazy\u00fcz M, et al. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry Investig. 2013;10(2):148.","journal-title":"Psychiatry Investig"},{"key":"1968_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112040","author":"D Liu","year":"2025","unstructured":"Liu D, et al. The effect of Fluoxetine on lipid profiles in overweight or obese individuals: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2025. https:\/\/doi.org\/10.1016\/j.diabres.2025.112040.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1968_CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jacl.2017.10.002","volume":"12","author":"A Delacr\u00e9taz","year":"2018","unstructured":"Delacr\u00e9taz A, et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. J Clin Lipidol. 2018;12(1):219\u201329.","journal-title":"J Clin Lipidol"},{"issue":"22","key":"1968_CR13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018686","volume":"9","author":"J Zambrano","year":"2020","unstructured":"Zambrano J, et al. Psychiatric and psychological interventions for depression in patients with heart disease: a scoping review. J Am Heart Assoc. 2020;9(22):e018686.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"1968_CR14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/ddc3040037","volume":"3","author":"G Hancu","year":"2024","unstructured":"Hancu G, Uil\u0103can A, Blebea NM. Chirality in modern antidepressants: a comprehensive review of stereochemical impacts on pharmacology and therapeutics. Drugs Drug Candidates. 2024;3(4):654\u201373.","journal-title":"Drugs Drug Candidates"},{"key":"1968_CR15","volume":"27","author":"DV Parums","year":"2021","unstructured":"Parums DV. Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Med Sci Monitor: Int Med J Experimental Clin Res. 2021;27:e934475\u20131.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"9","key":"1968_CR16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","volume":"89","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Reprint\u2014preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89(9):873\u201380.","journal-title":"Phys Ther"},{"key":"1968_CR17","doi-asserted-by":"crossref","unstructured":"Sterne JA et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019;366:l4898 .","DOI":"10.1136\/bmj.l4898"},{"key":"1968_CR18","unstructured":"Borenstein M, et al. Introduction to meta-analysis. Wiley; 2011."},{"issue":"1","key":"1968_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"1968_CR20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"2","key":"1968_CR21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1536867X0800800206","volume":"8","author":"TM Palmer","year":"2008","unstructured":"Palmer TM, et al. Contour-enhanced funnel plots for meta-analysis. The Stata Journal: Promoting communications on statistics and Stata. 2008;8(2):242.","journal-title":"The Stata Journal: Promoting communications on statistics and Stata"},{"key":"1968_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jad.2024.02.002","volume":"352","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xu Y, Xia Y. The efficacy and safety of Sertraline in maintenance hemodialysis patients with depression: a randomized controlled study. J Affect Disord. 2024;352:60\u20136.","journal-title":"J Affect Disord"},{"issue":"3","key":"1968_CR23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11332-022-00992-3","volume":"19","author":"MB Khameslo","year":"2023","unstructured":"Khameslo MB, et al. The effects of aerobic exercise and Sertraline on pro-inflammatory indices and amelioration of neurotrophic factors in patients who have undergone CABG. Sport Sci Health. 2023;19(3):969\u201378.","journal-title":"Sport Sci Health"},{"issue":"3","key":"1968_CR24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4103\/ijem.IJEM_67_19","volume":"23","author":"PR Kumar","year":"2019","unstructured":"Kumar PR, et al. Effect of sertraline as an add-on therapy in T2DM patients with comorbid depression: an open label randomized controlled trial. Indian J Endocrinol Metab. 2019;23(3):357\u201362.","journal-title":"Indian J Endocrinol Metab"},{"issue":"6","key":"1968_CR25","first-page":"801","volume":"31","author":"J Komorousova","year":"2010","unstructured":"Komorousova J, et al. Glycemic control improvement through treatment of depression using antidepressant drugs in patients with diabetes mellitus type 1. Neuro Endocrinol Lett. 2010;31(6):801\u20136.","journal-title":"Neuro Endocrinol Lett"},{"issue":"5","key":"1968_CR26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archpsyc.63.5.521","volume":"63","author":"PJ Lustman","year":"2006","unstructured":"Lustman PJ, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(5):521\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1968_CR27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.34067\/KID.0000062020","volume":"1","author":"LP Gregg","year":"2020","unstructured":"Gregg LP, et al. Depression and the effect of Sertraline on inflammatory biomarkers in patients with nondialysis CKD. Kidney360. 2020;1(6):436\u201346.","journal-title":"Kidney360"},{"issue":"5","key":"1968_CR28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/PSY.0000000000000301","volume":"78","author":"A Sherwood","year":"2016","unstructured":"Sherwood A, et al. Effects of exercise and Sertraline on measures of coronary heart disease risk in patients with major depression: results from the SMILE-II randomized clinical trial. Psychosom Med. 2016;78(5):602\u20139.","journal-title":"Psychosom Med"},{"issue":"4","key":"1968_CR29","first-page":"323","volume":"9","author":"E Razeghi","year":"2015","unstructured":"Razeghi E, et al. A randomized crossover clinical trial of Sertraline for intradialytic hypotension. Iran J Kidney Dis. 2015;9(4):323\u201330.","journal-title":"Iran J Kidney Dis"},{"issue":"3","key":"1968_CR30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.intimp.2013.09.020","volume":"17","author":"M Taraz","year":"2013","unstructured":"Taraz M, et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial. Int Immunopharmacol. 2013;17(3):917\u201323.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1968_CR31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/clpt.2009.121","volume":"86","author":"C Pizzi","year":"2009","unstructured":"Pizzi C, et al. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther. 2009;86(5):527\u201332.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1968_CR32","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc09-0785","volume":"32","author":"D Echeverry","year":"2009","unstructured":"Echeverry D, et al. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2009;32(12):2156\u201360.","journal-title":"Diabetes Care"},{"issue":"5","key":"1968_CR33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1176\/ajp.2006.163.5.893","volume":"163","author":"JP O\u2019Reardon","year":"2006","unstructured":"O\u2019Reardon JP, et al. A randomized, placebo-controlled trial of Sertraline in the treatment of night eating syndrome. Am J Psychiatry. 2006;163(5):893\u20138.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1968_CR34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","volume":"288","author":"AH Glassman","year":"2002","unstructured":"Glassman AH, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701\u20139.","journal-title":"JAMA"},{"issue":"6","key":"1968_CR35","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1176\/appi.ajp.157.6.1004","volume":"157","author":"SL McElroy","year":"2000","unstructured":"McElroy SL, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157(6):1004\u20136.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1968_CR36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1550-8528.1995.tb00189.x","volume":"3","author":"TA Wadden","year":"1995","unstructured":"Wadden TA, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995;3(6):549\u201357.","journal-title":"Obes Res"},{"issue":"11","key":"1968_CR37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03347875","volume":"19","author":"V Ricca","year":"1996","unstructured":"Ricca V, et al. Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients. J Endocrinol Invest. 1996;19(11):727\u201333.","journal-title":"J Endocrinol Invest"},{"key":"1968_CR38","doi-asserted-by":"crossref","DOI":"10.4137\/BMI.S38440","volume":"11","author":"SI Sherwani","year":"2016","unstructured":"Sherwani SI, et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:BMI.","journal-title":"Biomark Insights"},{"key":"1968_CR39","doi-asserted-by":"crossref","unstructured":"Brieler J, Salas J, Scherrer J. Achievement of glycemic control and antidepressant medication use in comorbid depression and type II diabetes. The Annals of Family Medicine; 2022.","DOI":"10.1370\/afm.20.s1.2902"},{"issue":"7","key":"1968_CR40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PSY.0000000000000707","volume":"81","author":"T Tharmaraja","year":"2019","unstructured":"Tharmaraja T, et al. The association between selective serotonin reuptake inhibitors and glycemia: a systematic review and meta-analysis of randomized controlled trials. Psychosom Med. 2019;81(7):570\u201383.","journal-title":"Psychosom Med"},{"issue":"7","key":"1968_CR41","volume":"6","author":"Z Ye","year":"2011","unstructured":"Ye Z, et al. Metabolic effects of Fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. PLoS ONE. 2011;6(7):e21551.","journal-title":"PLoS ONE"},{"key":"1968_CR42","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1590\/S0100-879X2001001200009","volume":"34","author":"R Gomez","year":"2001","unstructured":"Gomez R, et al. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz J Med Biol Res. 2001;34:1569\u201372.","journal-title":"Braz J Med Biol Res"},{"issue":"12","key":"1968_CR43","first-page":"1525","volume":"16","author":"M Kesim","year":"2011","unstructured":"Kesim M, et al. The effects of Sertraline on blood lipids, glucose, insulin and HBA1C levels: a prospective clinical trial on depressive patients. J Res Med Sciences: Official J Isfahan Univ Med Sci. 2011;16(12):1525.","journal-title":"J Res Med Sciences: Official J Isfahan Univ Med Sci"},{"issue":"9","key":"1968_CR44","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1111\/dom.15701","volume":"26","author":"K Toczyska","year":"2024","unstructured":"Toczyska K, et al. The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta-cell mass and function in vitro. Diabetes Obes Metab. 2024;26(9):3606\u201317.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1968_CR45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/01.jcp.0000132441.27854.0d","volume":"24","author":"P Ghaeli","year":"2004","unstructured":"Ghaeli P, et al. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol. 2004;24(4):386\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1968_CR46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13098-023-01149-z","volume":"15","author":"NS Alruwaili","year":"2023","unstructured":"Alruwaili NS, et al. Antidepressants and type 2 diabetes: highways to knowns and unknowns. Diabetol Metab Syndr. 2023;15(1):179.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1968_CR47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43045-025-00496-z","volume":"32","author":"L AL-Jahwari","year":"2025","unstructured":"AL-Jahwari L, et al. Effects of antidepressants on body weight in patients treated in a naturalistic setting in Oman. Middle East Curr Psychiatry. 2025;32(1):3.","journal-title":"Middle East Curr Psychiatry"},{"key":"1968_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-4-7","volume":"4","author":"M Paile-Hyv\u00e4rinen","year":"2003","unstructured":"Paile-Hyv\u00e4rinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003;4:1\u20136.","journal-title":"BMC Fam Pract"},{"key":"1968_CR49","unstructured":"Gill D, Hatcher S, Group CCMD. Antidepressants for depression in medical illness. Cochrane Database Syst Reviews, 1996. 2003(4): 1465-1858."},{"issue":"5","key":"1968_CR50","doi-asserted-by":"crossref","first-page":"e0196637","DOI":"10.1371\/journal.pone.0196637","volume":"13","author":"DL Swift","year":"2018","unstructured":"Swift DL, et al. Effects of aerobic training with and without weight loss on insulin sensitivity and lipids. PLoS ONE. 2018;13(5):e0196637.","journal-title":"PLoS ONE"},{"key":"1968_CR51","doi-asserted-by":"crossref","unstructured":"Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N EnglJ Med, 2002. 346(6): p. 393-403.","DOI":"10.1056\/NEJMoa012512"},{"issue":"10","key":"1968_CR52","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/biomedicines12102293","volume":"12","author":"V Katsi","year":"2024","unstructured":"Katsi V, et al. Weight loss therapies and hypertension benefits. Biomedicines. 2024;12(10):2293.","journal-title":"Biomedicines"},{"key":"1968_CR53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psyneuen.2016.02.012","volume":"68","author":"MG Silverstein-Metzler","year":"2016","unstructured":"Silverstein-Metzler MG, et al. Sertraline inhibits increases in body fat and carbohydrate dysregulation in adult female cynomolgus monkeys. Psychoneuroendocrinology. 2016;68:29\u201338.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"1968_CR54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","volume":"107","author":"E Beurel","year":"2020","unstructured":"Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neuron. 2020;107(2):234\u201356.","journal-title":"Neuron"},{"issue":"1","key":"1968_CR55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010578","volume":"24","author":"S Harsanyi","year":"2022","unstructured":"Harsanyi S, et al. Selected biomarkers of depression: what are the effects of cytokines and inflammation? Int J Mol Sci. 2022;24(1):578.","journal-title":"Int J Mol Sci"},{"key":"1968_CR56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.intimp.2018.12.011","volume":"67","author":"Y Lu","year":"2019","unstructured":"Lu Y, et al. Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-\u03b1-induced inflammation in microglia cells. Int Immunopharmacol. 2019;67:119\u201328.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1968_CR57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15171\/jrip.2017.12","volume":"6","author":"NS Zahed","year":"2016","unstructured":"Zahed NS, et al. Impact of sertraline on serum concentration of CRP in Hemodialysis patients with depression. J Renal Inj Prev. 2016;6(1):65.","journal-title":"J Renal Inj Prev"},{"key":"1968_CR58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pnpbp.2017.04.026","volume":"80","author":"M Wiedlocha","year":"2018","unstructured":"Wiedlocha M, et al. Effect of antidepressant treatment on peripheral inflammation markers-a meta-analysis. Prog Neuro-psychopharmacol Biol Psychiatry. 2018;80:217\u201326.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"issue":"12","key":"1968_CR59","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/npp.2011.132","volume":"36","author":"J Hannestad","year":"2011","unstructured":"Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"1968_CR60","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1017\/S0033291712000128","volume":"42","author":"S Hiles","year":"2012","unstructured":"Hiles S, et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med. 2012;42(10):2015\u201326.","journal-title":"Psychol Med"},{"issue":"12","key":"1968_CR61","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"1968_CR62","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-024-01259-7","volume":"27","author":"NN Mehta","year":"2024","unstructured":"Mehta NN, Degoma E, Shapiro MD. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024;27(1):12.","journal-title":"Curr Atheroscler Rep"},{"issue":"10285","key":"1968_CR63","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.","journal-title":"Lancet"},{"issue":"9","key":"1968_CR64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh M, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. 2022;10(9):645\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9349","key":"1968_CR65","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"Collaboration PS","year":"2002","unstructured":"Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903\u201313.","journal-title":"Lancet"},{"key":"1968_CR66","doi-asserted-by":"crossref","first-page":"704281","DOI":"10.3389\/fcvm.2021.704281","volume":"8","author":"A Calvi","year":"2021","unstructured":"Calvi A, et al. Antidepressant drugs effects on blood pressure. Front Cardiovasc Med. 2021;8:704281.","journal-title":"Front Cardiovasc Med"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01968-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01968-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:04:17Z","timestamp":1767470657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-01968-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01968-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}